News
Article
Author(s):
Preliminary data suggests that the exosomes could effectively address common skin concerns, including firmness, photodamage, and fine lines.
Elevai Labs, Inc., announced today in a press release promising results from its ongoing research in collaboration with Stanislav Sokolenko’s lab, an associate professor at Dalhousie University’s department of process engineering and applied science. The study highlights the potential of Elevai’s proprietary Precision Regenerative Exosome Technology (PREx) in producing exosomes with a unique protein profile that could advance skin health and aesthetics.1
“Exosomes from human umbilical cord-derived mesenchymal stem cells(hUMSCs) are known to contain many more proteins than exosomes from non-stem cell sources, like platelets or fibroblasts,” wrote Stanislav Sokolenko, PhD, P.Eng.. “However, this study further demonstrates that Elevai’s exosomes in particular, as compared to 54 previously published sets of exosome protein data, contain a distinct profile of proteins as compared to other mesenchymal stem cell (MSC) sources and are enriched for proteins commonly associated with skin and ECM remodeling, including collagen, fibrillin, TIMP2 and many others.”
Analysis of the samples revealed to researchers that Elevai exosomes displayed the expected morphology and size, as confirmed by transmission electron microscopy (TEM). Further, the release stated they were found to be rich in proteins associated with hemostasis, immunomodulation, wound healing, and ECM remodeling. Reactome pathway analysis indicated that these exosomes are particularly enriched in proteins related to skin health and ECM organization compared to existing data from other MSC sources.2
The study identified a range of significant proteins in Elevai exosomes, including various collagens, integrins, laminin fibers, fibronectin, fibulin, metalloproteinase inhibitors, and matrix metalloproteinases. The release states these proteins play crucial roles in maintaining skin elasticity, preventing thinning, and reducing wrinkle formation. The research highlighted that Elevai exosomes contained a statistically significant and notable enrichment of these proteins compared to 54 previously published exosome protein datasets.
“In this study, we were trying to answer whether our exosomes were fundamentally different than exosomes from other sources,” said Jordan R. Plews, chief executive officer of Elevai in the press release. “The data has led us to believe that, when appropriately processed through our PREx platform, our ethically sourced huMSCsrelease exosomes enriched with a profile of proteins similar to, but distinct from, other MSC sources.”
The PREx process, developed by Plews, is key to producing these advanced exosomes. Based on preliminary data, Elevai believes that PREx exosomes could be highly effective in addressing common skin concerns such as firmness, oxidative stress, photodamage, hyperpigmentation, and texture issues. The release stated they hold promise for reducing fine lines and wrinkles and improving overall skin health.
Elevai and Dalhousie University are planning further research to expand the scope of their protein studies and explore the broader applications of Elevai’s exosomes. The company stated future experiments will focus on assessing the impact of these exosomes on skin functions and exploring their potential in areas like bone regeneration, wound healing, and immune regulation. Elevai expects to release a comprehensive dataset by the end of the year.
This breakthrough research potentially offersnew solutions for skin rejuvenation and repair. As the company continues to advance its exosome technology, the company hopes it may pave the way for innovative treatments and enhancements in the field.
References